Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry-Reference-Cited by-同舟云学术

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Published:2021-04 Issue:4 Volume:84 Page:1000-1009
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Ariëns Lieneke F.M.,van der Schaft Jorien,Spekhorst Lotte S.,Bakker Daphne S.,Romeijn Geertruida L.E.,Kouwenhoven Tessa A.,Kamsteeg Marijke,Voorberg Angelique N.,Oosting Albert J.,de Ridder Ilona,Sloeserwij Annemieke,Haeck Inge,Thijs Judith L.,Schuttelaar Marie L.A.,de Bruin-Weller Marjolein S.

Funder

Regeneron Pharmaceuticals

Publisher

Elsevier BV

Subject

Dermatology

Reference28 articles.

1. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial;Blauvelt;Lancet,2017

2. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

3. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis;Simpson;N Engl J Med,2016

4. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial;Simpson;JAMA Dermatol,2020

5. Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study;Deleuran;J Am Acad Dermatol,2020

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis;JAMA Dermatology;2024-08-07

2. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials;The Lancet;2024-08

3. A risk-scoring system to predict dupilumab-associated ocular surface disease in patients with atopic dermatitis;Frontiers in Pharmacology;2024-08-01

4. Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis;Clinical and Translational Allergy;2024-08

5. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry;Journal of the American Academy of Dermatology;2024-08